# Mirum Pharmaceuticals, Inc. clinical trials: 40 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 40 trials with Mirum Pharmaceuticals, Inc. as lead sponsor, 6 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Mirum Pharmaceuticals, Inc.: 40 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/mirum-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 40
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 40, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07922733 | Expanded-Access Program for the Treatment of Chronic Hepatitis D With Brelovitug | Mirum Pharmaceuticals, Inc. | Not applicable | Available | Chronic Hepatitis, Delta Virus | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922733) |
| September 16, 2026 | NCT07823127 | MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy... | Mirum Pharmaceuticals, Inc. | Phase 2 | Not yet recruiting | Intrahepatic Cholestasis of Pregnancy | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823127) |
| July 17, 2026 | NCT07712718 | A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of \[14C\]-MRM-3379 | Mirum Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712718) |
| March 6, 2026 | NCT07454837 | Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide | Mirum Pharmaceuticals, Inc. | Phase 2/3 | Recruiting | Chronic Hepatitis D | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07454837) |
| December 23, 2025 | NCT07298330 | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) | Mirum Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | Chronic Hepatitis D Infection | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07298330) |
| December 18, 2025 | NCT07290257 | Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive... | Mirum Pharmaceuticals, Inc. | Phase 4 | Recruiting | Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07290257) |
| October 7, 2025 | NCT07209462 | Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) | Mirum Pharmaceuticals, Inc. | Phase 2 | Recruiting | Fragile X Syndrome | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07209462) |
| October 1, 2025 | NCT07200908 | A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) | Mirum Pharmaceuticals, Inc. | Phase 3 | Recruiting | Chronic Hepatitis D Infection | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07200908) |
| April 2, 2025 | NCT06907290 | A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection | Mirum Pharmaceuticals, Inc. | Phase 2/3 | Active not recruiting | Chronic Hepatitis D Infection | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06907290) |
| August 14, 2024 | NCT06553768 | Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Mirum Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06553768) |
| January 5, 2024 | NCT06193928 | Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) | Mirum Pharmaceuticals, Inc. | Observational | Recruiting | Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06193928) |
| September 20, 2021 | NCT05050136 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary... | Mirum Pharmaceuticals, Inc. | Phase 2 | Active not recruiting | Primary Biliary Cholangitis, PBC | 333 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05050136) |
| January 28, 2021 | NCT04729751 | A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive... | Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04729751) |
| January 22, 2021 | NCT04718961 | A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy... | Mirum Pharmaceuticals, Inc. | Phase 2 | Terminated | Intrahepatic Cholestasis of Pregnancy | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04718961) |
| December 11, 2020 | NCT04663308 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing... | Mirum Pharmaceuticals, Inc. | Phase 2 | Active not recruiting | Primary Sclerosing Cholangitis | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04663308) |
| August 28, 2020 | NCT04530994 | A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS) | Mirum Pharmaceuticals, Inc. | Not applicable | Approved for marketing | Alagille Syndrome | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04530994) |
| August 24, 2020 | NCT04524390 | Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai | Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | Biliary Atresia | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04524390) |
| February 17, 2020 | NCT04270682 | Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE) | Mirum Pharmaceuticals, Inc. | Phase 3 | Completed | CTX | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04270682) |
| December 4, 2019 | NCT04185363 | An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC) | Mirum Pharmaceuticals, Inc. | Phase 3 | Completed | Progressive Familial Intrahepatic Cholestasis (PFIC) | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04185363) |
| November 19, 2019 | NCT04168385 | MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a... | Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | Cholestatic Liver Disease | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04168385) |
| April 5, 2019 | NCT03905330 | A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) | Mirum Pharmaceuticals, Inc. | Phase 3 | Completed | Progressive Familial Intrahepatic Cholestasis (PFIC) | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03905330) |
| November 27, 2017 | NCT03353454 | A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) | Mirum Pharmaceuticals, Inc. | Phase 3 | Withdrawn | Progressive Familial Intrahepatic Cholestasis (PFIC) | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03353454) |
| April 14, 2017 | NCT03115086 | The REPLACE Registry for Cholbam® (Cholic Acid) | Mirum Pharmaceuticals, Inc. | Observational | Active not recruiting | Bile Acid Synthesis Disorders | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03115086) |
| June 1, 2016 | NCT02787304 | Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) | Mirum Pharmaceuticals, Inc. | Phase 2 | Terminated | Non-Alcoholic Steatohepatitis | 197 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02787304) |
| October 8, 2015 | NCT02571192 | A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose | Mirum Pharmaceuticals, Inc. | Phase 1 | Completed | Non-Alcoholic Steatohepatitis | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02571192) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 2 | 18 |
| Phase 2/3 | 2 |
| Phase 3 | 10 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 22 |
| Active not recruiting | 6 |
| Recruiting | 5 |
| Withdrawn | 2 |
| Terminated | 2 |
| Not yet recruiting | 1 |
| Approved for marketing | 1 |
| Available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Alagille Syndrome | 10 |
| Liver Diseases | 9 |
| Cholestasis | 9 |
| Cholestasis, progressive familial intrahepatic 1 | 8 |
| Bile Duct Diseases | 7 |
| Pruritus | 7 |
| Biliary Tract Diseases | 6 |
| Digestive System Diseases | 5 |
| Hepatitis D | 4 |
| Liver Cirrhosis, Biliary | 3 |
| Non-alcoholic Fatty Liver Disease | 3 |
| Cholangitis, Sclerosing | 3 |
| Zellweger Syndrome | 2 |
| Peroxisomal Disorders | 2 |
| Hepatitis D, Chronic | 2 |
| Intrahepatic Cholestasis of Pregnancy | 2 |
| Biliary Atresia | 2 |
| Fatty Liver | 1 |
| Refsum Disease, Infantile | 1 |
| Adrenoleukodystrophy | 1 |
| Xanthomatosis, Cerebrotendinous | 1 |
| Fragile X Syndrome | 1 |
| Congenital Abnormalities | 1 |
| Cholestasis, Intrahepatic | 1 |
| Cholangitis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Industrial equipment manufacturers in the United States](https://specstream.ai/data/businesses/industrial-equipment-manufacturers/united-states)
- [Building supply stores in the United States](https://specstream.ai/data/businesses/building-supply-stores/united-states)
- [Screen printers in the United States](https://specstream.ai/data/businesses/screen-printers/united-states)
- [Hostels in the United States](https://specstream.ai/data/businesses/hostels/united-states)
- [Beer bars in the United States](https://specstream.ai/data/businesses/beer-bars/united-states)
